



PATENT
Attorney Docket No. 209897

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lazarus et al.

Application No. 09/814,558

Filed: March 22, 2001

For: DMT-TIC DI-AND TRI-PEPTIDIC
DERIVATIVES AND RELATED
COMPOSITIONS AND METHODS OF
USE

Art Unit: 1653

Examiner: D. Lukton

#8/B
RECEIVED

MAR 14 2002 3/27/02
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 28, 2001, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

Please replace the paragraph on page 25, line 11, with the following:

B1 DAGO: H-Tyr-D-Ala-Gly-N-MePhe-Gly-ol (μ agonist) [SEQ ID NO:1]

Please replace the paragraph on page 25, line 12, with the following:

B2 DAMME: H-Tyr-D-Ala-Gly-N-MePhe-Met(O)-ol (μ agonist) [SEQ ID NO:2]

Please replace the paragraph on page 25, line 15, with the following:

B3 Deltorphan A: H-Tyr-D-Met-Phe-His-Leu-Met-NH₂ (δ_1 agonist) [SEQ ID NO:9]

Please replace the paragraph on page 25, line 16, with the following:

B4 Deltorphan B: H-Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH₂ (δ_2 agonist) [SEQ ID NO:3]

Please replace the paragraph on page 25, line 17, with the following:

B5 DER: dermorphin or H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂ (μ agonist) [SEQ ID NO:4]

Please replace the paragraph on page 25, line 21, with the following: